Nov 2 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP LATE-BREAKING ABSTRACT ACCEPTED FOR ORAL PRESENTATION ON FIRST-IN-CLASS LAG-3 THERAPEUTIC EFTILAGIMOD ALPHA AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2022 ANNUAL MEETING
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.5¢ | $43.98K | 177.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 175434 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 130922 | 14 |
View Market Depth
| Last trade - 10.43am 17/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |